X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab (PD-1 inhibitor) for the treatment of advanced endometrial cancer.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) is being evaluated for the treatment of MSI-H/dMMR Resectable Colon Cancer.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Through collaboration, Xuanzhu Biopharma will conduct a Phase 1b clinical study to evaluate the anti-tumor activity and safety of the combination therapy of sintilimab with KM-501 in Chinese patients with advanced solid tumors.
Lead Product(s): KM-501,Sintilimab
Therapeutic Area: Oncology Product Name: KM-501
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 27, 2023
Details:
Fruquintinib is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It being investigated in combination with sintilimab (PD-1 inhibitor) for advanced renal cell carcinoma in China.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: HMPL-013
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
The collaboration will focus on conducting clinical trials exploring combination therapies of the novel antibody-drug conjugates, RC88 (targeting MSLN) and RC108 (targeting c-MET), along with the PD-1 inhibitor sintilimab injection (TYVYT®).
Lead Product(s): RC88,Sintilimab
Therapeutic Area: Oncology Product Name: RC88
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 09, 2023
Details:
Under the agreement, Innovent will provide supplies of TYVYT® (sintilimab injection) and RemeGen will conduct Phase 1/2a studies to evaluate the anti-tumor activity of the combination therapy of TYVYT® with RC88 or RC108 in Chinese patients with advanced solid tumors.
Lead Product(s): RC88,Sintilimab
Therapeutic Area: Oncology Product Name: RC88
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 25, 2023
Details:
China NMPA approves TYVYT® (sintilimab injection), an antibody that inhibits PD-1, in combination with bevacizumab and chemotherapy in patients with EGFR-mutated non-squamous NSCLC who progressed after EGFR-TKI therapy.
Lead Product(s): Sintilimab,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
IBI110, an IgG4κ recombinant human anti-LAG-3 monoclonal antibody independently developed by Innovent Biologics. Based on clinical needs, Innovent has carried out clinical studies to explore PK/PD characteristics of IBI110 single agent and combined with sintilimab in humans.
Lead Product(s): IBI110,Sintilimab
Therapeutic Area: Oncology Product Name: IBI110
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.Fruquintinib is being developed in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Tyvyt (sintilimab) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,IBI305,Pemetrexed
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
The combination therapy consists of Laekna’s afuresertib (LAE002), a highly selective ATP competitive AKT inhibitor in clinical trials with favorable efficacy and safety profile, and Innovent’s PD-1 inhibitor sintilimab (TYVYT), which has been approved for six indications.
Lead Product(s): Sintilimab,Afuresertib,Paclitaxel
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Sintilimab, marketed as TYVYT in China, is a PD-1 immunoglobulin G4 monoclonal antibody, is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on surface of T-cells, blocks PD-L1 pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Based on interim analysis conducted by IDMC,Tyvyt (sintilimab) in combination with chemotherapy demonstrated a statistically significant improvement in primary endpoint of OS compared to placebo in combination with chemotherapy regardless of PD-L1 expression status.
Lead Product(s): Sintilimab,Cisplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
39 patients with advanced solid tumors who failed standard of care therapy were treated with IBI110 (≥ 3 mg/kg) in combination with sintilimab and received at least 1 post-baseline tumor assessment. 6 patients achieved PR, ORR was 15.4% and DCR was 64.1%.
Lead Product(s): IBI110,Sintilimab
Therapeutic Area: Oncology Product Name: IBI110
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
The NMPA BTD for IBI310 was based on results from First part of a Phase 2 trial of IBI310 in combination with sintilimab showed potential for this combination as a new treatment option for patients in need.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
IBI389 is an anti-CLDN18.2/CD3 bispecific antibody discovered and developed by Innovent. It induces immune synapse formations by linking CD3 molecules in T-cell receptor complexes and CLDN18.2 antigens on the surfaces of tumor cells.
Lead Product(s): IBI389,Sintilimab
Therapeutic Area: Oncology Product Name: IBI389
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Tyvyt (sintilimab), an investigational PD-1 inhibitor a type of immunoglobulin G4 monoclonal antibody, binds to PD-1 molecules on surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Tyvyt (sintilimab),is a novel PD-1 inhibitor, is under review for the first-line treatment of people with non-squamous non-small cell lung cancer based on the ORIENT-11 trial conducted exclusively in China.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2022
Details:
TYVYT (sintilimab injection), is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-L1 pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2022
Details:
LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.
Lead Product(s): Afuresertib,Sintilimab,Undisclosed
Therapeutic Area: Oncology Product Name: LAE002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2022
Details:
Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
Lead Product(s): Sintilimab,Bevacizumab,Pemetrexed
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
Sintilimab, with or without BYVASDA® (bevacizumab biosimilar injection), combined with chemotherapy (pemetrexed and cisplatin) in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: IBI308
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2021
Details:
ORIENT-12 is Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) or placebo in combination with GEMZAR® (gemcitabine) and platinum chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Sintilimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
The presentations include the data from Phase 3 trials of sintilimab in esophageal squamous cell carcinoma and gastric cancer which are disclosed for the first time, as well as results from studies of IBI310 and pemigatinib.
Lead Product(s): Sintilimab,Cisplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2021
Details:
The safety profile of sintilimab in this study was consistent with that observed in previously reported studies of sintilimab, and no additional safety signals were identified for the combination of sintilimab and chemotherapy.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2021
Details:
The companies will work together to conduct clinical studies assessing the combination of sintilimab and afuresertib (LAE002) in patients with multiple types of solid tumors that have been refractory-or failed to respond-to treatment with PD-1/PD-L1 inhibitors.
Lead Product(s): Sintilimab,Afuresertib
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 05, 2021
Details:
The safety profile of sintilimab in this study was consistent with that observed in previously reported studies of sintilimab, and no additional safety signals were identified.
Lead Product(s): Sintilimab,Cisplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
ORIENT-32 is a Phase 2/3, open label, multi-center study conducted to evaluate the efficacy and safety of sintilimab in combination with the bevacizumab biosimilar IBI305 compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2021
Details:
A total of 397 patients were enrolled and randomized 2:1 to receive either sintilimab 200mg or placebo in combination with pemetrexed and platinum chemotherapy every 3 weeks for up to four cycles, followed by either sintilimab or placebo plus pemetrexed maintenance therapy.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
NCT04720716 is a randomized, open-label, controlled, multicenter phase III study evaluating the efficacy and safety of IBI310 in combination with TYVYT® (sintilimab injection) for advanced HCC patients.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
Details:
This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3)—evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy.
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
The Phase 2 clinical trial will be evaluating the efficacy and safety of IBI310 versus placebo, in combination with TYVYT, for advanced cervical cancer patients who have failed first and later line or intolerant of platinum-based chemotherapy.
Lead Product(s): IBI310,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) demonstrated significantly improved overall survival and Independent Radiographic Review Committee progression-free survival versus sorafenib.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
The seven studies of TYVYT® (sintilimab injection) to be presented on ESMO ASIA include one Proffered Paper Oral Presentation (a Phase 3 study) and six e-posters, covering indications including lung cancer, liver cancer, gastric cancer, and esophageal cancer.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Innovent Biologics announce the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with global expansion collaboration agreement between the company and Eli Lilly for TYVYT (sintilimab injection).
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration October 07, 2020
Details:
The ORIENT-32 trial evaluating TYVYT® in combination with BYVASDA® as a first-line treatment in advanced hepatocellular carcinoma met the predefined primary endpoints of progression-free survival (PFS) and overall survival (OS) in an interim analysis.
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
ORIENT-12 is the first randomized, double-blind, Phase 3 clinical trial evaluating TYVYT® or placebo in combination with GEMZAR® and platinum chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Sintilimab,Gemcitabine,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
TYVYT is the only PD-1 inhibitor to be included in China's National Reimbursement Drug List (NRDL) and is included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,025.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement August 18, 2020
Details:
National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application for TYVYT® (sintilimab injection) in combination with Gemzar® (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung cancer (squamous NSCLC).
Lead Product(s): Sintilimab,Gemcitabine,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
TYVYT® (sintilimab injection) in combination with ALIMTA® (pemetrexed) and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS) compared with placebo in combination with ALIMTA® (pemetrexed) and platinum chemotherapy.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2020
Details:
CIBI391A101 is a Phase 1b clinical study conducted in China to evaluate sintilimab plus surufatinib in the treatment of patients with advanced malignancies.
Lead Product(s): Sintilimab,Surufatinib
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
The study is an open-label study and was consisted of two parts, Phase 1a study and Phase 1b study, designed to evaluate the tolerability, safety and anti-tumor activity of IBI310 and its combination with sintilimab in the treatment of subjects with advanced malignant tumors.
Lead Product(s): IBI310,Sintilimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
The collaboration aims at providing opportunities for Innovent to pursue approval of sintilimab by the U.S. FDA for multiple rare cancer indications in addition to larger cancer indications for sintilimab that Innovent is independently pursuing for approval as well.
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: MD Anderson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 18, 2020
Details:
Data highlighted shows continued progress on clinical trials for the KEYTRUDA LENVIMA combination across multiple tumor types, including presentation on Phase 2 results of the metastatic clear cell renal cell carcinoma cohort of a Phase 1b/2 study of KEYTRUDA + LENVIMA.
Lead Product(s): Sintilimab,Cisplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
TYVYT in combination with gemcitabine+ platinum chemotherapy demonstrated significant improvement in PFS compared to placebo+ gemcitabine and platinum chemotherapy.
Lead Product(s): Sintilimab,Gemcitabine,Platinum
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
The NDA was based on the pre-specified interim analysis of a Phase 3 clinical trial Tyvyt or placebo in combination with ALIMTA and platinum as first-line therapy for Non-squamous NSCLC.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Based on the interim analysis, sintilimab in combination with ALIMTA and platinum demonstrated a statistically significant improvement in PFS compared with placebo with ALIMTA and platinum combo.
Lead Product(s): Sintilimab,Pemetrexed,Platinum
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2020
Details:
The firms have entered into a mutual partnership to perform clinical studies using Sirnaomics' RNAi drug candidate STP705 and Tyvyt by Innovent and , for combination treatment in advanced cancers.
Lead Product(s): Sintilimab,Cotsiranib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
